CR8426A - ANTI-IGF-I RECEIVER ANTIBODY - Google Patents
ANTI-IGF-I RECEIVER ANTIBODYInfo
- Publication number
- CR8426A CR8426A CR8426A CR8426A CR8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- igf
- cancer
- receptor
- elevated levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotoxicos, que especificamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-l, IGF-lI y suero en el crecimiento y supervivencia de celulas de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjuncion con otros agente terapeuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-l, tales como cancer de pecho, cancer de colon, cancer de pulmon, sarcoma sinovial, cancer de prostata, y cancer pancreatico, y los anticuerpos derivatizados se pueden utilizar en el diagnostico y formacion de imagenes de tumores que expresan niveles elevados del IGF-I.Antibodies, humanized antibodies, coated antibodies, antibody fragments, derivatized antibodies and conjugated thereof with cytotoxic agents, which specifically bind to, and inhibit the insulin-like growth factor I receptor, antagonize the effects of IGF-1. , IGF-lI and serum in the growth and survival of tumor cells, and which substantially lack agonist activity. The antibodies and fragments thereof can therefore be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors expressing elevated levels of the IGF-1 receptor, such as breast cancer, colon cancer, lung cancer, Synovial sarcoma, prostate cancer, and pancreatic cancer, and derivatized antibodies can be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/729,441 US8034904B2 (en) | 2002-06-14 | 2003-12-08 | Anti-IGF-I receptor antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8426A true CR8426A (en) | 2007-12-04 |
Family
ID=36616549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8426A CR8426A (en) | 2003-12-08 | 2006-06-01 | ANTI-IGF-I RECEIVER ANTIBODY |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1692176A4 (en) |
JP (1) | JP2008502589A (en) |
KR (1) | KR20070001883A (en) |
CN (1) | CN1886424A (en) |
AU (1) | AU2004303792A1 (en) |
BR (1) | BRPI0417406A (en) |
CA (1) | CA2548065A1 (en) |
CR (1) | CR8426A (en) |
EA (1) | EA009807B1 (en) |
EC (1) | ECSP066595A (en) |
IL (1) | IL174770A0 (en) |
MX (1) | MXPA06005540A (en) |
NO (1) | NO20063155L (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG181834A1 (en) | 2009-12-21 | 2012-07-30 | Genentech Inc | Antibody formulation |
NZ603972A (en) * | 2010-05-11 | 2014-11-28 | Aveo Pharmaceuticals Inc | Anti-fgfr2 antibodies |
EP2766478A4 (en) | 2011-10-10 | 2015-06-17 | Los Angeles Childrens Hospital | Novel asparaginase and methods for treating diseases associated with asparagine dependence |
CN103509117B (en) * | 2013-05-06 | 2016-03-09 | 江苏匡亚生物医药科技有限公司 | Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use |
CA3056573A1 (en) * | 2017-05-30 | 2018-12-06 | Teijin Pharma Limited | Anti-igf-i receptor antibody |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143514A0 (en) * | 1998-12-04 | 2002-04-21 | Novartis Ag | METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3 |
ME00502B (en) * | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antibodies to insulin-like growth factor i receptor |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
CN101164616A (en) * | 2003-02-13 | 2008-04-23 | 辉瑞产品公司 | Uses of anti-insulin-like growth factor 1 receptor antibodies |
-
2004
- 2004-12-07 MX MXPA06005540A patent/MXPA06005540A/en active IP Right Grant
- 2004-12-07 CN CNA200480034889XA patent/CN1886424A/en active Pending
- 2004-12-07 EA EA200600931A patent/EA009807B1/en not_active IP Right Cessation
- 2004-12-07 JP JP2006543832A patent/JP2008502589A/en active Pending
- 2004-12-07 AU AU2004303792A patent/AU2004303792A1/en not_active Abandoned
- 2004-12-07 EP EP04811082A patent/EP1692176A4/en not_active Ceased
- 2004-12-07 KR KR1020067010010A patent/KR20070001883A/en not_active Application Discontinuation
- 2004-12-07 CA CA002548065A patent/CA2548065A1/en not_active Abandoned
- 2004-12-07 BR BRPI0417406-2A patent/BRPI0417406A/en not_active IP Right Cessation
-
2006
- 2006-04-04 IL IL174770A patent/IL174770A0/en unknown
- 2006-05-31 EC EC2006006595A patent/ECSP066595A/en unknown
- 2006-06-01 CR CR8426A patent/CR8426A/en not_active Application Discontinuation
- 2006-07-07 NO NO20063155A patent/NO20063155L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004303792A1 (en) | 2005-07-07 |
ECSP066595A (en) | 2006-10-17 |
MXPA06005540A (en) | 2006-08-17 |
JP2008502589A (en) | 2008-01-31 |
EP1692176A4 (en) | 2008-11-12 |
CN1886424A (en) | 2006-12-27 |
EA009807B1 (en) | 2008-04-28 |
IL174770A0 (en) | 2006-08-20 |
BRPI0417406A (en) | 2007-04-03 |
CA2548065A1 (en) | 2005-07-07 |
EA200600931A1 (en) | 2006-10-27 |
NO20063155L (en) | 2006-08-11 |
EP1692176A1 (en) | 2006-08-23 |
KR20070001883A (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG141243A1 (en) | Anti-igf-i receptor antibody | |
AR061911A1 (en) | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER | |
PE20080663A1 (en) | TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES | |
ES2571235T3 (en) | Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody | |
CR8426A (en) | ANTI-IGF-I RECEIVER ANTIBODY | |
TW200635606A (en) | Anti-integrin immunoconjugates, methods and uses | |
AR070862A1 (en) | COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS | |
AR061245A1 (en) | COMPOSITIONS AND METHODS FOR VASCULAR DEVELOPMENT MODULATION | |
UA99608C2 (en) | PDGFRb-SPECIFIC INHIBITORS | |
NO20070945L (en) | Induction of apoptosis in tumor cells expressing Toll-like receptor | |
PT2326665E (en) | Non-cytotoxic fusion proteins comprising egf muteins | |
AR054254A1 (en) | ADJUTIVE THERAPY WITH TRASTUZUMAB (REGISTERED HERCEPTIN) | |
MX2020009463A (en) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy. | |
NZ599707A (en) | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ) | |
EP1909783A4 (en) | Illudin analogs useful as anticancer agents | |
EA200601405A1 (en) | HUMANIZED ANTIBODY | |
WO2011137245A3 (en) | Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use | |
MX2009010269A (en) | Methods of treating cancer by administering human il-18 combinations. | |
PE20130460A1 (en) | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS | |
Heller et al. | Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer | |
JP2018516230A5 (en) | ||
Sandomenico | 3D1, a novel anti-nodal monoclonal antibody to target melanoma | |
DOP2009000003A (en) | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER | |
Heidegger et al. | The Impact of Insulin Receptors on IGF1R Targeting Therapies in Prostate Cancer. | |
PE20091437A1 (en) | CANCER DISEASE MODIFYING ANTIBODIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |